Gastrointestinal Imaging

What Imaging Is Best for Surveillance After Pancreatic Neuroendocrine Tumor Resection?

·
What Imaging Is Best for Surveillance After Pancreatic Neuroendocrine Tumor Resection?

A 58-year-old patient is in your clinic for a one-year follow-up visit. Last year, they underwent a distal pancreatectomy for a well-differentiated, non-functioning pancreatic neuroendocrine tumor (pNET). They feel well, have no new symptoms, and their recent lab work, including chromogranin A, is unremarkable. You know that surveillance imaging is a critical part of their long-term care, but the question is which study to order today. The goal is to detect potential recurrence early while minimizing unnecessary radiation and cost. This article provides a clinical workflow for this exact scenario, guided by the American College of Radiology (ACR) Appropriateness Criteria, which rate a `CT abdomen and pelvis with IV contrast` as Usually appropriate.

Who Fits This Clinical Scenario?

This guidance is for a specific patient population: adults who have undergone complete surgical resection of a pancreatic neuroendocrine tumor and are now in the surveillance phase. The key inclusion criteria are:

  • Prior complete surgical resection of a pNET.
  • No current symptoms concerning for recurrence (e.g., new abdominal pain, jaundice, flushing, or diarrhea).
  • No known or suspected recurrence based on clinical evaluation or biochemical markers.

This workflow is explicitly not for patients who are undergoing initial staging before treatment, as that requires a different imaging strategy to evaluate for metastatic disease. It also does not apply to patients with known residual disease, those with liver-dominant metastases being treated non-surgically, or those with untreated tumors under observation. Each of those situations represents a distinct clinical question with its own recommended imaging pathway. The focus here is purely on routine, scheduled surveillance in an asymptomatic, post-operative patient.

What Diagnoses Are You Working Up in This Scenario?

In surveillance imaging for a resected pNET, the primary goal is the early detection of asymptomatic tumor recurrence. The differential for a new finding on imaging is narrow but critical, focusing on the locations where these tumors most commonly reappear.

Distant Metastases (Hepatic): The liver is the most common site for pNET recurrence. These tumors are typically hypervascular, meaning they have a rich blood supply. Detecting small, new liver lesions when they are asymptomatic allows for a broader range of treatment options, including resection, ablation, or liver-directed embolization therapies. The surveillance scan is optimized to find these specific lesions.

Local or Regional Recurrence: Recurrence can occur in the surgical bed (local) or in nearby lymph nodes (regional). While less common than liver metastases, identifying these early is crucial. A new soft tissue mass near the pancreatic remnant or enlarging retroperitoneal lymph nodes would be highly suspicious in this context.

Distant Metastases (Extra-hepatic): Though less frequent, pNETs can also recur in the bones or lungs. While a dedicated abdominal CT is not the primary modality for bone or lung screening, it can often detect osseous lesions in the visualized spine and pelvis or nodules at the lung bases, prompting further investigation if seen.

Why Is CT Abdomen and Pelvis with IV Contrast the Recommended Study?

For routine surveillance in an asymptomatic patient after pNET resection, the ACR designates `CT abdomen and pelvis with IV contrast` as a Usually appropriate study. The rationale is based on a balance of diagnostic accuracy, accessibility, and efficiency for detecting the most likely forms of recurrence.

The key to identifying pNET recurrence, particularly in the liver, is intravenous contrast. Pancreatic neuroendocrine tumors and their metastases are typically hypervascular, meaning they enhance avidly and early after contrast administration. A multiphasic CT protocol, which includes late arterial and portal venous phase imaging, is essential. The arterial phase highlights the hypervascular lesions against the less-enhanced background liver parenchyma, making them conspicuous. The portal venous phase is crucial for evaluating the pancreas itself, regional lymph nodes, and the portal vein for any signs of tumor involvement.

While CT is the primary recommendation, other modalities are rated for specific circumstances:

  • MRI abdomen and pelvis without and with IV contrast: This is rated May be appropriate (Disagreement). MRI can offer superior soft-tissue contrast and may be more sensitive for detecting small liver metastases. However, it is more costly, less widely available, and more time-consuming than CT, making it a less practical choice for routine, repeated surveillance in an asymptomatic patient. It is often reserved as a problem-solving tool for equivocal CT findings.
  • DOTATATE PET/CT: Also rated May be appropriate, this functional imaging study targets somatostatin receptors, which are overexpressed on most well-differentiated pNETs. It is highly sensitive and specific. However, it involves a higher radiation dose (☢☢☢ 1-10 mSv) and cost, and is generally reserved for situations with a higher clinical or biochemical suspicion of recurrence, or to clarify ambiguous findings on anatomic imaging like CT.

The recommended CT carries a relative radiation level of ☢☢☢ (1-10 mSv). For patients requiring lifelong surveillance, this cumulative dose is a consideration, but the benefit of early detection often outweighs the risk. A `CT chest abdomen pelvis with IV contrast` is also rated Usually appropriate and may be considered if there is a higher risk of thoracic metastases, though it comes with a higher radiation dose (☢☢☢☢ 10-30 mSv).

Once you’ve decided on the appropriate study, our protocol guide covers the technical details. For technique, contrast, and reading principles, see our guide: CT Chest/Abdomen/Pelvis with IV Contrast.

What’s Next After CT? Downstream Workflow

The results of the surveillance CT will guide the next steps in management. The workflow branches based on whether the findings are negative, positive, or indeterminate.

If the study is negative: A negative or stable surveillance scan is the desired outcome. The patient can continue with their scheduled follow-up plan. The frequency of subsequent imaging depends on the grade, stage, and characteristics of the original tumor, with guidelines from organizations like the North American Neuroendocrine Tumor Society (NANETS) or European Neuroendocrine Tumor Society (ENETS) providing a framework for timing.

If the study is positive for suspected recurrence: If a new, suspicious lesion is identified in the liver, surgical bed, or regional lymph nodes, the next step is confirmation and staging. This often involves discussion at a multidisciplinary tumor board. Further characterization with a problem-solving study like a multiphasic liver MRI or a functional scan like a DOTATATE PET/CT is typically performed. Depending on the location and size, a biopsy may be needed to confirm the diagnosis before initiating treatment.

If the study is indeterminate: Sometimes, a finding is ambiguous—for example, a tiny new liver lesion that is too small to characterize. In this case, the management options include a short-interval follow-up CT (e.g., in 3 months) to assess for change, or proceeding directly to a more sensitive imaging modality like MRI or DOTATATE PET/CT to better characterize the finding and avoid delays in diagnosis if it is indeed a recurrence.

Pitfalls to Avoid (and When to Get Help)

Several common pitfalls can compromise the effectiveness of pNET surveillance. First, ordering a CT of the abdomen and pelvis without IV contrast is a critical error, as it will likely miss the hypervascular liver metastases that are the primary target of the scan. Second, failing to adhere to a consistent surveillance schedule based on tumor risk can lead to either delayed diagnosis or unnecessary radiation exposure. Third, it is important to correlate imaging findings with biochemical markers (e.g., chromogranin A, specific hormone levels for functional tumors), as a rising marker may increase suspicion for recurrence even with equivocal imaging. If imaging findings are complex, subtle, or discordant with the clinical picture, escalation to a multidisciplinary tumor board with expertise in neuroendocrine tumors is the most appropriate next step.

Related ACR Topics and Tools

This article covers one specific surveillance scenario. For a comprehensive overview of imaging for pancreatic neuroendocrine tumors across all clinical presentations, from initial staging to follow-up of advanced disease, please consult our parent topic hub article. Additionally, several GigHz tools can help streamline your clinical workflow.

Frequently Asked Questions

How often should surveillance CT scans be performed after pNET resection?

The frequency of surveillance imaging depends on the grade and stage of the resected tumor. Low-grade (G1), early-stage tumors may be imaged annually, while higher-grade (G2/G3) or higher-stage tumors often require more frequent surveillance, such as every 6-12 months, especially in the first few years after surgery. Consult guidelines from NANETS or ENETS for specific recommendations.

Is MRI a better choice than CT for surveillance in all post-resection pNET patients?

Not necessarily for routine surveillance. While MRI may have slightly higher sensitivity for small liver metastases, the ACR rates it as ‘May be appropriate (Disagreement)’. For an asymptomatic patient, CT with IV contrast offers an excellent balance of accuracy, speed, cost, and availability. MRI is often better used as a problem-solving tool for equivocal CT findings or in patients with a contraindication to iodinated contrast.

When should I order a DOTATATE PET/CT for surveillance instead of a CT?

A DOTATATE PET/CT is generally not the first-line imaging modality for routine surveillance in an asymptomatic patient due to higher cost and radiation exposure. It is rated ‘May be appropriate’ and is best reserved for situations where there is a clinical or biochemical (e.g., rising chromogranin A) suspicion of recurrence, or to clarify indeterminate findings seen on a CT or MRI.

What if my patient has a contraindication to IV contrast, like a severe allergy or renal failure?

In cases of severe iodinated contrast allergy or significant renal impairment, a contrast-enhanced CT may not be feasible. An MRI of the abdomen and pelvis, often with a gadolinium-based contrast agent (if renal function permits), becomes the preferred alternative. A non-contrast MRI can also provide valuable information but is less sensitive for hypervascular lesions.

Does this surveillance guidance apply to poorly differentiated neuroendocrine carcinomas (NECs)?

No, this guidance is tailored for well-differentiated pancreatic neuroendocrine tumors (pNETs). Poorly differentiated neuroendocrine carcinomas (NECs) are much more aggressive and often do not express somatostatin receptors. Their surveillance and staging frequently involve FDG-PET/CT, which is rated ‘Usually not appropriate’ for routine pNET surveillance, reflecting the different biology of these cancers.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026